SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia shares are under pressure as traders debate the boards investigation into CEO Jensen Huangs relationship with a woman alleged to be a Chinese spy, and the potential leadership and national-security implications. The community is split between fears that further scrutiny could force Huang out and dip-buyers who view the selloff as an overreaction to personal allegations, while watching upcoming earnings for a business update.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

A disappointing Q3 reportwith a surprise loss, squeezed margins, weaker-than-expected outlook and a sequential subscriber declinehas driven a sharp selloff. Traders are split between concerns about profitability and execution and hopes that international growth, the Lilly partnership and the planned Peptides+ launch can support a recovery.

Digital Turbine, Inc. engages in mobile growth platform solutions for advertisers, publishers, carriers, and device original equipment manufacturers. It operates through the following segments: On Device Solutions and App Growth Platform. The On Device Solutions segment consists of products and services that simplify the discovery and delivery of mobile apps and content media for device end users. The App Growth Platform segment provides Advertising Solutions and Ad Monetization Solutions. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

Digital Turbine shares are plunging despite a quarterly revenue beat and raised revenue outlook, as traders focus on gross-margin compression from higher partner payouts and unchanged EBITDA guidance. Bulls call the selloff excessive given the companys growth, while skeptics question whether it can turn that growth into stronger profits and cite its debt burden.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Q3 earnings beat and stronger-than-expected outlook sparked a sharp initial rally, but shares gave back much of the move during the call. Traders are split between seeing progress toward a turnaround, with the expanded buyback and short interest as potential supports, and worrying that flat-to-declining revenue, one-time tailwinds, and managements cautious tone undermine the results.

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,203,846.69715353. The last known price of Ethereum is 2,121.02700944 USD and is down -0.91 over the last 24 hours. It is currently trading on 14303 active market(s) with $13,174,532,202.61 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

Ethereum is under pressure in a broader crypto selloff, with traders pointing to hot U.S. inflation and renewed Federal Reserve rate-hike concerns alongside Bitcoins decline and a wave of leveraged-long liquidations. The community is split between expecting further downside and treating the pullback as a buying opportunity.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.09792366 USD and is down -1.80 over the last 24 hours. It is currently trading on 1894 active market(s) with $2,759,095,442.76 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRPs sharp decline alongside a broader crypto selloff is driving attention, with traders citing risk-off sentiment, rate-hike concerns and leveraged liquidations. The discussion is split between bearish calls for further losses and holders who view the oversold drop as a buying opportunity while watching key support.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors pending FDA decision on deramiocel is the dominant focus, with traders centering on the November 22 decision and the amended applications upper-limb-function case for Duchenne muscular dystrophy. Many are optimistic about approval and a potential short squeeze, while others stress the binary risk and FDA skepticism; the AHA award for cardiac research adds to bullish sentiment but does not resolve the regulatory uncertainty.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARAs quarterly report has driven attention, with traders weighing a profit beat tied largely to Bitcoin gains against weaker mining revenue. The debt reduction and share-repurchase authorization drew optimism, while the lack of major AI/HPC tenant leases and continued Bitcoin exposure remain points of concern.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics Q3 results and higher full-year revenue guidance, driven by continued BRIUMVI growth, are the main focus. Traders largely view the business update positively despite an initial selloff and sharp reversal; many are watching the upcoming subcutaneous BRIUMVI Phase 3 readout, while buyout and short-squeeze talk remains speculative.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Labs quarterly results are driving discussion: revenue and backlog growth beat expectations, but a wider-than-expected loss and Neutrons first launch being pushed to 2027 weighed on shares. Traders are split between viewing the loss as largely tied to Iridium-related costs and seeing the Neutron delay and profitability as key risks.

statis crypto Watchlist

Bitcoin

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Candels latest SITC immune-response and viral-shedding data for aglatimagene are drawing attention as the company prepares a planned FDA application for its prostate-cancer treatment, following positive Phase 3 results. Bulls see the data as strengthening the filing package, while skeptics focus on submission timing, manufacturing and management transparency; recent share weakness is also attributed by some traders to broader biotech-market pressure.

No specific company, sector, or macro catalyst clearly explains the move, which appears tied to broader trading activity.

Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up Next 

Equity

Moderna will report on Friday, while the SITC meeting will bring fresh cancer-treatment findings from Immunocore and Candel.

Dow, S&P 500, Nasdaq Futures Edge Higher After Fed Delivers Rate Hike: SPCX, CADL, SNAP, FLNC Stocks In Focus

The Federal Reserve On Wednesday hiked benchmark interest rates by 25 bps to a target range of 3.75% to 4.00%, in line with market expectations. 

The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux 

Prostate cancer awareness spotlights Pfizer's Xtandi, Novartis' Pluvicto and clinical-stage programs from Candel and Janux.

4 Prostate Cancer Drug Stocks to Watch During Awareness Month

Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.

CADL Rises As Biotech Eyes First Commercial Product in 2027 — CEO Points To ‘Meaningful Execution’ Toward BLA Submission In Q4

If the FDA approves aglatimagene besadenovec in the treatment of certain patients with prostate cancer, it would mark the company’s first commercial product. 


CADL Stock In Focus As Candel Nears Year-End BLA Filing For Prostate Cancer Drug —  Eyes $10–$16B Opportunity 

Shares of Candel have drawn rising attention as the company advances its experimental immunotherapy, known as CAN-2409 or aglatimagene, toward potential approval in localized prostate cancer.


CADL Stock Heads For Biggest Monthly Gains Since December 2024 – Retail Says ‘Our SLS Days Are Coming’

Candel Therapeutics announced the initiation of a Phase 3 trial evaluating lead therapy CAN-2409 in advanced non-small cell lung cancer patients.

CADL Stock Heads For Best Week In A Month – Here’s Why Retail Is Bullish

Candel Therapeutics Phase 3 prostate cancer trial showed a higher disease-free survival rate.

Wall Street Analysts Believe Candel Therapeutics (CADL) Could Rally 148.48%: Here's is How to Trade

The mean of analysts' price targets for Candel Therapeutics (CADL) points to a 148.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data

Candel Therapeutics presented positive phase 3 prostate cancer data showing improved disease-free survival, while analysts maintained bullish expectations on the stock.read more...

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>Vertex will report results on Monday, putting Journavx and Casgevy sales and its $10 billion Crinetics acquisition in focus.</li><li>Pfizer and BioNTech report on Tuesday, with Pfizer’s newer medicines and recent cancer-treatment advances drawing attention.</li><li>Amgen reports Tuesday and Novo Nordisk follows on Wednesday, spotlighting MariTide’s development and Wegovy sales.</li></ul><p>Biotech stocks head into a busy earnings week after beating the broader market, with Pfizer, Novo Nordisk and Moderna set to report earnings alongside a fresh round of cancer-treatment data.&nbsp;</p><p>Healthcare and biotech rallied the previous week, with the&nbsp;<a href="https://stocktwits.com/symbol/IBB">iShares Biotechnology ETF (IBB)</a> gaining 5%, the&nbsp;<a href="https://stocktwits.com/symbol/XBI">SPDR S&amp;P Biotech ETF (XBI)</a> climbing 4%, and the&nbsp;<a href="https://stocktwits.com/symbol/XLV">Health Care Select Sector SPDR Fund (XLV)</a> rising 3%. Comparatively, the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF Trust (SPY)</a> fell 0.6%, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> dropped 2%.</p><p><img src="https://news.stocktwits-cdn.com/koyfin_20261102_072345224_2e2499ab82.png" alt="koyfin_20261102_072345224.png"></p><div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col></colgroup><tbody><tr><td>Date</td><td>Ticker/Event</td><td>What To Watch</td></tr><tr><td>Nov.2</td><td>VRTX</td><td>Q3 results</td></tr><tr><td>Nov.3</td><td>PFE / AMGN / BNTX / MDGL</td><td>Q3 results</td></tr><tr><td>Nov.3</td><td>SITC</td><td>Regular abstracts become public&nbsp;</td></tr><tr><td>Nov.4</td><td>NVO</td><td>Q3 results</td></tr><tr><td>Nov.4 - Nov.8</td><td>SITC</td><td>Cancer-immunotherapy meeting in Phoenix</td></tr><tr><td>Nov.5</td><td>IOVA</td><td>Q3 results</td></tr><tr><td>Nov.6</td><td>MRNA</td><td>Q3 results</td></tr><tr><td>Nov.6</td><td>SITC / IMCR / CADL</td><td>Late-breaking abstracts release; Immunocore and Candel presentations</td></tr><tr><td>Nov.7</td><td>IMCR / CADL</td><td>Immunocore oral presentation and Candel glioblastoma findings</td></tr></tbody></table></figure></div><h2 class="st-heading-2"><strong>Vertex Looks Beyond Cystic Fibrosis</strong></h2><p>Vertex Pharmaceuticals will report results on Monday after the close, with investors looking for more growth from medicines outside its core cystic-fibrosis business.</p><p>Its non-opioid pain drug Journavx brought in $49.6 million in second-quarter sales, while gene-editing treatment Casgevy generated $76.4 million. In August, Vertex raised its full-year revenue forecast to $13.1 billion to $13.2 billion, including at least $500 million from the two drugs. That forecast did not include its $10 billion acquisition of Crinetics Pharmaceuticals, completed Sept.1. The deal added Palsonify, a once-daily pill for acromegaly, a disorder caused by excess growth hormone.&nbsp;</p><h2 class="st-heading-2"><strong>Pfizer Puts Its Cancer Business To The Test</strong></h2><p>Pfizer (PFE) will report on Tuesday, after a busy week for its cancer business. The FDA cleared Talzenna plus Xtandi for earlier use in metastatic prostate cancer with certain DNA-repair gene mutations. The next day, Pfizer said Elrexfio helped patients live longer without their multiple myeloma worsening in a Phase 3 trial against standard treatments. Researchers are still collecting data to determine its effect on overall survival.</p><p>For the earnings report, the question is whether newer medicines can keep making up for weaker COVID-related sales. Revenue from Pfizer’s launched and acquired products grew 18%, excluding currency effects, in the second quarter, helping the company raise the midpoint of its annual revenue forecast by $500 million.</p><p>BioNTech, Pfizer’s COVID-vaccine partner, also reports Tuesday.</p><h2 class="st-heading-2"><strong>Amgen And Novo Bring Obesity Back Into View</strong></h2><p>Amgen (AMGN) will report on Tuesday after the close, with an update on its obesity drug MariTide among the items to watch. Its Phase 3 Maritime program is studying weight management as well as cardiovascular disease, heart failure and sleep apnea. A separate trial is testing injections every eight weeks or quarterly in patients switching from weekly Tirzepatide or Semaglutide. Less frequent dosing could give patients another reason to choose the treatment if it wins approval.</p><p>Novo Nordisk (NVO) will report on Wednesday, with sales of the Wegovy pill and higher-dose injection offering a check on demand. Weekly U.S. prescriptions for the pill topped 265,000 by mid-July. Novo raised its outlook in August, though it still expected adjusted sales and operating profit to range from a 6% decline to no growth, excluding currency effects.</p><p>Madrigal Pharmaceuticals (MDGL) also will report on Tuesday, giving investors a look at demand for its liver-disease drug Rezdiffra.</p><h2 class="st-heading-2"><strong>Iovance Balances Melanoma Sales With Lung-Cancer Plans</strong></h2><p>Iovance Biotherapeutics (IOVA) will report on Thursday. Investors will get an update on Amtagvi, a treatment that uses patients’ own immune cells to fight advanced melanoma, as the company works to expand into lung cancer.</p><p>Results released last month showed a 24.6% response rate among 69 previously treated lung-cancer patients. That rose to 59.1% in a 22-patient subgroup identified using tumor genetics and smoking history. Iovance plans to begin enrolling its Positility cohort in November to test that selection strategy prospectively. A filing for Lifileucel in the broader previously treated lung-cancer population is planned for 2027.</p><h2 class="st-heading-2"><strong>Moderna’s Earnings Go Beyond Vaccine Sales</strong></h2><p>Moderna (MRNA) will report on Friday, with investors weighing seasonal vaccine sales alongside progress on its personalized cancer vaccine. The company previously targeted up to 10% revenue growth for 2026 and expected about 55% of its second-half revenue to come in the third quarter.</p><p>Its update could also bring more detail on regulatory plans for Intismeran Autogene. Last month, Moderna and Merck (MRK) said the experimental vaccine, combined with Merck’s immunotherapy Keytruda, reduced the risk of melanoma recurrence or death by 42% compared with Keytruda alone in a Phase 3 trial. Overall-survival data are still being collected.</p><h2 class="st-heading-2"><strong>New Cancer Findings Arrive At SITC</strong></h2><p>The Society for Immunotherapy of Cancer’s annual meeting and pre-conference programs run Nov.4-Nov.8 in Phoenix. Regular research abstracts become public on Tuesday, followed by late-breaking findings on Friday.</p><p>Immunocore (IMCR) will present early results for Brenetafusp alone and with Kimmtrak in metastatic uveal melanoma, an eye cancer that has spread. Both drugs help direct immune cells called T cells to attack cancer. Additionally, Candel Therapeutics (CADL) will present lung-cancer findings Friday in patients whose disease progressed despite earlier immunotherapy. On Saturday, it will share early findings in recurrent glioblastoma, an aggressive brain cancer.</p><h2 class="st-heading-2"><strong>Inovio Gets FDA Approval As Agios Faces A Delay</strong></h2><p>Two names from last week’s FDA watchlist head into November with different outcomes: an approval for Inovio Pharmaceuticals (INO) and a longer wait for Agios Pharmaceuticals (AGIO).</p><p>On Friday, the FDA granted accelerated approval to Inovio’s Voceryq, formerly INO-3107, for adults with recurrent respiratory papillomatosis. The rare HPV-related disease causes recurring airway growths that can require repeated surgery.&nbsp;</p><p>Meanwhile, the FDA extended its review of Agios’ Mitapivat for sickle cell disease to Feb.1, 2027, from Nov.1. The agency is considering whether a risk-management program is needed and classified additional safety information as a major amendment, triggering the three-month extension.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spcx-stock-musk-tsmc-terafab-talks-capex-efficiency-greatly-underestimated/cNG9KfcR92f">SPCX Stock Jumps Overnight: Musk Reportedly Revives TSMC Terafab Talks — Says Capex Efficiency Is ‘Greatly Underestimated’&nbsp;</a></p>

Biotech Stocks Beat The S&P500 – Can Pfizer, Novo And Moderna Earnings Keep The Rally Going?

Agios Pharmaceuticals Inc

AMGEN Inc.

BioNTech SE - ADR

iShares Biotechnology ETF

Immunocore Holdings PLC - ADR

Inovio Pharmaceuticals Inc

Iovance Biotherapeutics Inc

Madrigal Pharmaceuticals Inc

Merck & Co Inc

Moderna Inc

Novo Nordisk A/S

Pfizer Inc

Vertex Pharmaceuticals, Inc.

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

Investors are closely watching the upcoming Q4 Biologics License Application filing, which many see as the primary driver for potential valuation growth.

Clinical data from SITC 2026 suggests the platform effectively converts immune-desert tumors into responsive ones by inducing systemic cytotoxic T-cell activity.

Market attention is high for the ongoing randomized Phase 3 lung cancer trial, which offers a clean read on survival benefits compared to docetaxel.

Low float dynamics and high institutional ownership are fueling discussions about a potential rapid share price appreciation near year-end.

Recent executive appointments are viewed as a calculated move to transition the company into a commercial-stage oncology player ahead of approval.

Feed

News

Sentiment

Earnings

Fundamentals

Info

CADL News